Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

被引:5
|
作者
Takamatsu, Kiyoshi [1 ]
Ogawa, Mariko [1 ]
Higuchi, Tsuyoshi [2 ]
Takeda, Takashi [3 ]
Hayashi, Kunihiko [4 ]
Mizunuma, Hideki [5 ]
机构
[1] Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Obstet & Gynecol, Sugano 5-11-13, Ichikawa, Chiba 2728513, Japan
[2] Hirosaki Univ, Grad Sch Hlth Sci, Dept Nursing Sci, Zaifu Cho 5, Hirosaki, Aomori 0368562, Japan
[3] Kindai Univ, Res Inst Tradit Asian Med, Div Womens Hlth, Oonohigashi 377-2, Osaka Sayama City, Osaka 5898511, Japan
[4] Gunma Univ, Grad Sch Hlth Sci, Dept Int Community Hlth Lab Sci, Showa Machi 3-39-22, Maebashi, Gunma 3718514, Japan
[5] Fukushima Med Univ, Fukushima Med Ctr Children & Women, Hikariga Oka 1, Fukushima, Fukushima 9601295, Japan
关键词
HORMONE-REPLACEMENT-THERAPY; KAMI-SHOYO-SAN; POSTMENOPAUSAL WOMEN;
D O I
10.1155/2020/9285317
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. Kampo medicine, a traditional Japanese medicine, is widely used in Japan, especially in the field of menopause medicine. However, few studies have shown evidence-based effects. This study aimed to confirm the effects of kamishoyosan on menopausal symptoms with a randomized, placebo-controlled, double-blind clinical trial.Methods. Subjects were randomly allocated to groups that received either kamishoyosan (n = 101) or a placebo resembling kamishoyosan (n = 104). The primary outcomes were the change in the number of hot flashes, depression scores, improvements of anxiety, quality of life (QOL), and menopausal symptoms before and 4 and 8 weeks after initiation of treatment with the study drug. The secondary outcome was drug safety.Results. After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups. The changes in SDS scores showed the same results. Moreover, no significant differences were observed between the two groups in assessments with the STAI, SF-36, and JSOG menopausal index. No serious adverse effect was reported.Conclusions. This first placebo-controlled double-blind randomized trial with kamishoyosan demonstrated that it was safe and had some effects on climacteric symptoms, but not significant compared with placebo. Some problems, such as placebo effects, in the study of Kampo therapy for menopausal symptoms, were revealed. This trial is registered with the trial registration number. UMIN 000006042.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The effects of synbiotic supplementation on oxidative stress and clinical symptoms in women with migraine: A double-blind, placebo-controlled, randomized trial
    Ghavami, Abed
    Khorvash, Fariborz
    Khalesi, Saman
    Heidari, Zahra
    Askari, Gholamreza
    JOURNAL OF FUNCTIONAL FOODS, 2021, 86
  • [32] JinqiJiangtang tablets for prediabetes: A randomized, double-blind and placebo-controlled clinical trial
    Wang, Hui
    Guo, Liping
    Shang, Hongcai
    Ren, Ming
    Wang, Xuemei
    Wang, Dehui
    Chen, Jianzong
    Li, Shuanglei
    Chen, Liming
    Wang, Yue
    Liu, Zhi
    Zhai, Jingbo
    Song, Yuzhen
    Cao, Hongbo
    Zhang, Junhua
    Liu, Chunxiang
    Sun, Xiao
    Huo, Da
    Mu, Wei
    Zhang, Li
    Zheng, Wenke
    Yan, Xiaoyan
    Yao, Chen
    SCIENTIFIC REPORTS, 2017, 7
  • [33] CHOLECALCIFEROL SUPPLEMENTATION AND INFLAMMATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Seibert, Eric
    Ulrich, Christof
    Trojanowicz, Bogusz
    Lehmann, Ulrike
    Dierkes, Jutta
    Stangl, Gabriele I.
    Girndt, Matthias
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [34] Effects ofPorphyra teneraSupplementation on the Immune System: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial
    Jung, Su-Jin
    Jang, Hui-Yeon
    Jung, Eun-Soo
    Noh, Soon-Ok
    Shin, Sang-Wook
    Ha, Ki-Chan
    Baek, Hyang-Im
    Ahn, Byung-Jae
    Oh, Tae-Hwan
    Chae, Soo-Wan
    NUTRIENTS, 2020, 12 (06)
  • [35] Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial
    Ranasinghe, Priyanga
    Wathurapatha, Wasundara S.
    Galappatthy, Priyadarshani
    Katulanda, Prasad
    Jayawardena, Ranil
    Constantine, Godwin R.
    JOURNAL OF DIABETES, 2018, 10 (05) : 386 - 397
  • [36] A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Omalizumab For Chronic Rhinosinusitis
    Mehta, N. J.
    Pinto, J.
    de Tineo, M.
    Baroody, F. M.
    Naclerio, R. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S201 - S201
  • [37] Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial
    Gualano, Bruno
    Ugrinowitsch, Carlos
    Novaes, Rafael Batista
    Artioli, Guilherme Gianini
    Shimizu, Maria Heloisa
    Seguro, Antonio Carlos
    Harris, Roger Charles
    Lancha, Antonio Herbert, Jr.
    EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2008, 103 (01) : 33 - 40
  • [38] Effects of oxcarbazepine versus carbamazepine on tinnitus: A randomized double-blind placebo-controlled clinical trial
    Gerami, Hooshang
    Saberi, Alia
    Nemati, Shadman
    Kazemnejad, Ehsan
    Aghajanpour, Mohammad
    IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 106 - 110
  • [39] Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial
    Bruno Gualano
    Carlos Ugrinowitsch
    Rafael Batista Novaes
    Guilherme Gianini Artioli
    Maria Heloisa Shimizu
    Antonio Carlos Seguro
    Roger Charles Harris
    Antonio Herbert Lancha
    European Journal of Applied Physiology, 2008, 103 : 33 - 40
  • [40] Effect of ritanserin on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial
    Akhondzadeh, Shahin
    Malek-Hosseini, Mojgan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (02) : 304 - 304